Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016166586> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2016166586 endingPage "76" @default.
- W2016166586 startingPage "71" @default.
- W2016166586 abstract "Women without versus those with vertebral fracture may have different benefits and risks during raloxifene treatment. Our objective was to compare the effects of raloxifene to decrease risk for vertebral fracture and invasive breast cancer with its effect to increase risk for venous thromboembolism in postmenopausal women without or with baseline vertebral fracture.The Multiple Outcomes of Raloxifene Evaluation trial included postmenopausal women with osteoporosis randomized to placebo, raloxifene 60 mg/day, or raloxifene 120 mg/day for 4 years. The protocol specified subgroups based on whether or not patients had a vertebral fracture at baseline. Absolute differences between placebo and raloxifene 60 mg/day (the approved dose) for endpoints in these groups were defined as the incidence in the raloxifene group minus the incidence in the placebo group.Raloxifene decreased the incidence of vertebral fracture and invasive breast cancer while increasing the incidence of venous thromboembolism. All treatment by vertebral fracture status interaction p-values were greater than 0.13, indicating that the effect of raloxifene on these outcomes was not significantly different between patients without versus those with vertebral fractures. In women without baseline vertebral fracture, absolute risk differences between the raloxifene and placebo group included vertebral fracture -2.83%, invasive breast cancer -1.21%, and venous thromboembolism +0.28%. In women with baseline vertebral fracture, absolute risk differences between raloxifene and placebo group included vertebral fracture -8.21%, invasive breast cancer -0.75% and venous thromboembolism +0.91%. The analysis had limited power to test whether raloxifene had a significantly different effect on venous thromboembolism in women without versus those with a vertebral fracture.In women without and in those with vertebral fractures at baseline, the effects of raloxifene to decrease vertebral fracture and invasive breast cancer were greater than its effects to increase venous thromboembolism." @default.
- W2016166586 created "2016-06-24" @default.
- W2016166586 creator A5005253974 @default.
- W2016166586 creator A5071267554 @default.
- W2016166586 creator A5081307533 @default.
- W2016166586 date "2009-11-12" @default.
- W2016166586 modified "2023-09-26" @default.
- W2016166586 title "Benefits and risks of raloxifene by vertebral fracture status" @default.
- W2016166586 cites W175660244 @default.
- W2016166586 cites W1773789492 @default.
- W2016166586 cites W1986364825 @default.
- W2016166586 cites W2003219279 @default.
- W2016166586 cites W2009621819 @default.
- W2016166586 cites W2053591982 @default.
- W2016166586 cites W2067905926 @default.
- W2016166586 cites W2078303139 @default.
- W2016166586 cites W2090972405 @default.
- W2016166586 cites W2112629831 @default.
- W2016166586 cites W2170750104 @default.
- W2016166586 cites W2172185687 @default.
- W2016166586 doi "https://doi.org/10.1185/03007990903427082" @default.
- W2016166586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19908937" @default.
- W2016166586 hasPublicationYear "2009" @default.
- W2016166586 type Work @default.
- W2016166586 sameAs 2016166586 @default.
- W2016166586 citedByCount "11" @default.
- W2016166586 countsByYear W20161665862013 @default.
- W2016166586 countsByYear W20161665862017 @default.
- W2016166586 countsByYear W20161665862018 @default.
- W2016166586 countsByYear W20161665862019 @default.
- W2016166586 countsByYear W20161665862023 @default.
- W2016166586 crossrefType "journal-article" @default.
- W2016166586 hasAuthorship W2016166586A5005253974 @default.
- W2016166586 hasAuthorship W2016166586A5071267554 @default.
- W2016166586 hasAuthorship W2016166586A5081307533 @default.
- W2016166586 hasConcept C120195587 @default.
- W2016166586 hasConcept C120665830 @default.
- W2016166586 hasConcept C121332964 @default.
- W2016166586 hasConcept C121608353 @default.
- W2016166586 hasConcept C126322002 @default.
- W2016166586 hasConcept C126894567 @default.
- W2016166586 hasConcept C141071460 @default.
- W2016166586 hasConcept C142724271 @default.
- W2016166586 hasConcept C204787440 @default.
- W2016166586 hasConcept C27081682 @default.
- W2016166586 hasConcept C2776541429 @default.
- W2016166586 hasConcept C2777176818 @default.
- W2016166586 hasConcept C2779889926 @default.
- W2016166586 hasConcept C29456083 @default.
- W2016166586 hasConcept C44249647 @default.
- W2016166586 hasConcept C530470458 @default.
- W2016166586 hasConcept C61511704 @default.
- W2016166586 hasConcept C71924100 @default.
- W2016166586 hasConceptScore W2016166586C120195587 @default.
- W2016166586 hasConceptScore W2016166586C120665830 @default.
- W2016166586 hasConceptScore W2016166586C121332964 @default.
- W2016166586 hasConceptScore W2016166586C121608353 @default.
- W2016166586 hasConceptScore W2016166586C126322002 @default.
- W2016166586 hasConceptScore W2016166586C126894567 @default.
- W2016166586 hasConceptScore W2016166586C141071460 @default.
- W2016166586 hasConceptScore W2016166586C142724271 @default.
- W2016166586 hasConceptScore W2016166586C204787440 @default.
- W2016166586 hasConceptScore W2016166586C27081682 @default.
- W2016166586 hasConceptScore W2016166586C2776541429 @default.
- W2016166586 hasConceptScore W2016166586C2777176818 @default.
- W2016166586 hasConceptScore W2016166586C2779889926 @default.
- W2016166586 hasConceptScore W2016166586C29456083 @default.
- W2016166586 hasConceptScore W2016166586C44249647 @default.
- W2016166586 hasConceptScore W2016166586C530470458 @default.
- W2016166586 hasConceptScore W2016166586C61511704 @default.
- W2016166586 hasConceptScore W2016166586C71924100 @default.
- W2016166586 hasIssue "1" @default.
- W2016166586 hasLocation W20161665861 @default.
- W2016166586 hasLocation W20161665862 @default.
- W2016166586 hasOpenAccess W2016166586 @default.
- W2016166586 hasPrimaryLocation W20161665861 @default.
- W2016166586 hasRelatedWork W1619501556 @default.
- W2016166586 hasRelatedWork W2016166586 @default.
- W2016166586 hasRelatedWork W2043416310 @default.
- W2016166586 hasRelatedWork W2313008369 @default.
- W2016166586 hasRelatedWork W2473225074 @default.
- W2016166586 hasRelatedWork W2905624307 @default.
- W2016166586 hasRelatedWork W3107290693 @default.
- W2016166586 hasRelatedWork W4292258670 @default.
- W2016166586 hasRelatedWork W4299314417 @default.
- W2016166586 hasRelatedWork W2188522152 @default.
- W2016166586 hasVolume "26" @default.
- W2016166586 isParatext "false" @default.
- W2016166586 isRetracted "false" @default.
- W2016166586 magId "2016166586" @default.
- W2016166586 workType "article" @default.